Silence Therapeutics (SLN) Receivables (2019 - 2025)

Silence Therapeutics has disclosed Receivables across 7 years of filings, most recently posting $28000.0 for Q3 2025.

• Receivables for Q3 2025 came in at $28000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $28000.0 (changed N/A YoY), and the FY2024 annual result was $972000.0, up 235.17% from the prior year.
• Receivables came in at $28000.0 for Q3 2025 at Silence Therapeutics, down from $85000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.1 million in Q4 2022 to a low of $28000.0 in Q3 2025.
• The 5-year median for Receivables is $282982.6 (2023), against an average of $418343.4.
• Across the five-year window, Receivables plunged 98.85% in 2021 and jumped 243.48% in 2024, its largest moves.
• Silence Therapeutics' Receivables stood at $446191.5 in 2021, then surged by 140.53% to $1.1 million in 2022, then tumbled by 73.63% to $282982.6 in 2023, then surged by 243.48% to $972000.0 in 2024, then tumbled by 97.12% to $28000.0 in 2025.
• The last three Receivables figures came in at $28000.0 (Q3 2025), $85000.0 (Q2 2025), and $41000.0 (Q1 2025), per Business Quant data.